Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial

Pediatric Infectious Disease Journal

Volumn 27, Issue 5, 2008, Pages 444-452

  Gaglani, Manjusha J ^a,c   Piedra, Pedro A ^b   Riggs, Mark ^a   Herschler, Gayla ^a   Fewlass, Charles ^a   Glezen, W Paul ^b  

^a TEXAS A AND M UNIVERSITY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

asthma, wheezing; cold adapted; intranasal influenza vaccine; live attenuated; trivalent

Indexed keywords

INFLUENZA VACCINE; LIVE ATTENUATED INFLUENZA VACCINE; LIVE VACCINE; TRIPLE VACCINE; UNCLASSIFIED DRUG;

ACUTE RESPIRATORY TRACT DISEASE; ADULT; ARTICLE; ASTHMA; CHILD; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE DRUG DOSE; WHEEZING; ABNORMAL RESPIRATORY SOUND; ADOLESCENT; COMPARATIVE STUDY; IMMUNOLOGY; INFANT; INFLUENZA; INTRANASAL DRUG ADMINISTRATION; PRESCHOOL CHILD;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ASTHMA; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN; RESPIRATORY SOUNDS; VACCINES, ATTENUATED;

EID: 45849151764     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181660c2e     Document Type: Article

References (52)

1. Glezen WP. Asthma, influenza, and vaccination. J Allergy Clin Immunol. 2006;118:1199 -1206.
2. Jartti T, Lehtinen P, Vuorinen T, et al. Respiratory picornaviruses and respiratory syncytial virus as causative agents of acute expiratory wheezing in children. Emerg Infect Dis. 2004;10:1095-1101.
3. Glezen WP. Reactive airway disorders in children. Role of respiratory virus infections. Clin Chest Med. 1984;5:635- 643.
4. Erhart LM, Rangel MC, Lu PJ, Singleton JA. Prevalence and characteristics of children at increased risk for complications from influenza, United States, 2000. J Pediatr. 2004;144:191-195.
5. Glezen WP, Greenberg SB, Atmar RL, Piedra PA, Couch RB. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA. 2000;283:499 -505.
6. Neuzil KM, Wright PF, Mitchel EF Jr, Griffin MR. The burden of influenza illness in children with asthma and other chronic medical conditions. J Pediatr. 2000;137:856-864.
7. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recomm Rep 2007;56: 1-54.
8. Gaglani MJ. Rationale and approach to target children with asthma for annual influenza immunization. Semin Pediatr Infect Dis. 2002;13:97-103.
9. Gnanasekaran S, Finkelstein J, Lozano P, Farber HJ, Chi FW, Lieu TA. Influenza vaccination among children with asthma in Medicaid managed care. Ambul Pediatr. 2006;6:1-7.
10. Dombkowski K, Davis MM, Cohn LM, Clark SJ. Effect of missed opportunities on influenza vaccination rates among children with asthma. Arch Pediatr Adolesc Med. 2006;160:966 -971.
11. Daley MF, Beaty BL, Barrow J, et al. Missed opportunities for influenza vaccination in children with chronic medical conditions. Arch Pediatr Adolesc Med. 2005;159:986 -991.
12. Paul IM, Eleoff SB, Shaffer ML, Bucher RM, Moyer KM, Gusic ME. Improving influenza vaccination rates for children through year-round scheduling. Ambul Pediatr. 2006;6:230 -234.
13. Martin E. Improving influenza vaccination rates in a pediatric asthma management program by utilization of an electronic medical record. Clin Pediatr(Phila). 2006;45:221-227.
14. Daley MF, Barrow J, Pearson K, et al. Identification and recall of children with chronic medical conditions for influenza vaccination. Pediatrics. 2004;113(1 Pt 1):e26-e33.
15. Gaglani M, Riggs M, Kamenicky C, Glezen WP. A computerized reminder strategy is effective for annual influenza immunization of children with asthma or reactive airway disease. Pediatr Infect Dis J. 2001;20:1155-1160.
16. Centers for Disease Control and Prevention (CDC). Influenza vaccination coverage among children with asthma-United States, 2004-05 influenza season. MMWR Morb Mortal Wkly Rep 2007;56:193-196.
17. Hambidge SJ, Glanz JM, France EK, et al. Vaccine Safety Datalink Team. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. JAMA. 2006;296:1990 -1997.
18. France EK, Glanz JM, Xu S, et al. Safety of the trivalent inactivated influenza vaccine among children: a population-based study. Arch Pediatr Adolesc Med. 2004;158:1031-1036.
19. Goodman MJ, Nordin JD, Harper P, Defor T, Zhou X. The safety of trivalent influenza vaccine among healthy children 6 to 24 months of age. Pediatrics. 2006;117:e821- e826.
20. The safety of inactivated influenza vaccine in adults and children with asthma. N Engl J Med 2001;345:1529 -1536.
21. Zangwill KM, Belshe RB. Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination. Pediatr Infect Dis J. 2004;23:189 -197.
22. Ritzwoller DP, Bridges CB, Shetterly S, Yamasaki K, Kolczak M, France EK. Effectiveness of the 2003-2004 influenza vaccine among children 6 months to 8 years of age, with 1 vs. 2 doses. Pediatrics. 2005;116:153-159.
23. Allison MA, Daley MF, Crane LA, et al. Influenza vaccine effectiveness in healthy 6- to 21-month-old children during the 2003-2004 season. J Pediatr. 2006;149:755-762.
24. Centers for Disease Control and Prevention (CDC). Childhood influenza accination coverage-United States, 2004-05 influenza season. MMWR orb Mortal Wkly Rep 2006;55:1062-1065.
25. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live ttenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in hildren. N Engl J Med. 1998;338:1405-1412.
26. Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination ith live attenuated, cold-adapted, trivalent, intranasal influenza virus accine against a variant (A/Sydney) not contained in the vaccine. Pediatr. 2000;136:168 -175.
27. Longini IM, Halloran ME, Nizam A, et al. Estimation of the efficacy of ive, attenuated influenza vaccine from a two-year, multi-center vaccine rial: implications for influenza epidemic control. Vaccine. 2000;18: 902-1909.
28. Piedra PA, Yan L, Kotloff K, Zangwill K, et al. Safety of the trivalent, old-adapted influenza vaccine in preschool-aged children. Pediatrics. 002;110:662- 672.
29. Bergen R, Black S, Shinefield H, et al. Safety of cold-adapted live ttenuated influenza vaccine in a large cohort of children and adolescents. ediatr Infect Dis J. 2004;23:138 -144.
30. Centers for Disease Control and Prevention (CDC). Notice to readers: xpansion of use of live attenuated influenza vaccine (FluMist®) to hildren aged 2- 4 years and other flumist changes for the 2007- 08 nfluenza season. MMWR Morb Mortal Wkly Rep 2007;56:1217-1219.
31. Morgan WJ, Stern DA, Sherrill DL, et al. Outcome of asthma and heezing in the first 6 years of life: follow-up through adolescence. Am J espir Crit Care Med. 2005;172:1253-1258.
32. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan J. Asthma and wheezing in the first six years of life. The Group Health edical Associates. N Engl J Med. 1995;332:133-138.
33. Piedra PA, Gaglani MJ, Riggs M, et al. Live attenuated influenza accine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, pen-label trial. Pediatrics. 2005;116:e397- e407.
34. Piedra PA, Gaglani MJ, Kozinetz CA, et al. Herd immunity in adults against nfluenza-related illnesses with use of the trivalent-live attenuated influenza accine (CAIV-T) in children. Vaccine. 2005;23:1540-1548.
35. Gaglani MJ, Piedra PA, Herschler GB, et al. Direct and total effectiveness f the intranasal, live-attenuated, trivalent cold-adapted influenza irus vaccine against the 2000-2001 influenza A (H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med. 2004;158:65-73.
36. Halloran ME, Longini IM Jr, Gaglani MJ, et al. Estimating efficacy of rivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures. Am J Epidemiol. 2003;158:305-311.
37. Halloran ME, Piedra PA, Longini IM Jr, et al. Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004. Vaccine. 2007;25:4038-4045.
38. Piedra PA, Gaglani MJ, Kozinetz CA, et al. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics. 2007;120:e553- e564.
39. Osborne ML, Vollmer WM, Johnson RE, et al. Use of an automated prescription database to identify individuals with asthma. J Clin Epidemiol. 1995;48:1393-1397.
40. Griffin MR, Taylor JA, Daugherty JR, Ray WA. No increased risk for invasive bacterial infection found following diphtheria-tetanus-pertussis immunization. Pediatrics. 1992;89:640-642.
41. Griffin MR, Ray WA, Mortimer EA, Fenichel GM, Schaffner W. Risk of seizures after measles-mumps-rubella immunization. Pediatrics. 1991;88:881- 885.
42. Selvin S. Chapter 12: Poisson regression analysis. In: Practical Biostatistical Methods. Belmont, CA: Duxbury Press; 199
43. Ledley FD, Brody B, Kozinetz CA, Mize SG. The challenge of follow-up for clinical trials of somatic gene therapy. Hum Gene Ther. 1992;3:657- 663.
44. Breslow N. Multivariate cohort analysis. Natl Cancer Inst Monogr. 1985;67:149 -156.
45. Redding G, Walker RE, Hessel C, et al. Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J. 2002;21:44-48.
46. Vesikari T, Karvonen A, Korhonen T, et al. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr Infect Dis J. 2006;25:590 -595.
47. King JC Jr, Stoddard JJ, Gaglani MJ, et al. Effectiveness of school-based influenza vaccination. N Engl J Med. 2006;355:2523-2532.
48. Vesikari T, Fleming DM, Aristegui JF, et al. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics. 2006;118:2298 -2312.
49. Ashkenazi S, Vertruyen A, Aristegui J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J. 2006;25:870-879.
50. Izurieta HS, Haber P, Wise RP, et al. Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA. 2005;294:2720-2725.
51. Fleming DM, Crovari P, Wahn U, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J. 2006;25:860-869.
52. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007;356:685- 696.